PT2252300T - Utilização de 2,4-pirimidinadiaminas para tratamento da aterosclerose - Google Patents

Utilização de 2,4-pirimidinadiaminas para tratamento da aterosclerose

Info

Publication number
PT2252300T
PT2252300T PT97119440T PT09711944T PT2252300T PT 2252300 T PT2252300 T PT 2252300T PT 97119440 T PT97119440 T PT 97119440T PT 09711944 T PT09711944 T PT 09711944T PT 2252300 T PT2252300 T PT 2252300T
Authority
PT
Portugal
Prior art keywords
pyrimidinediamines
atherosclerosis
treatment
Prior art date
Application number
PT97119440T
Other languages
English (en)
Inventor
Masuda Esteban
Schmitz Jochen
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of PT2252300T publication Critical patent/PT2252300T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Materials For Medical Uses (AREA)
PT97119440T 2008-02-22 2009-02-20 Utilização de 2,4-pirimidinadiaminas para tratamento da aterosclerose PT2252300T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3090308P 2008-02-22 2008-02-22

Publications (1)

Publication Number Publication Date
PT2252300T true PT2252300T (pt) 2017-01-06

Family

ID=40559977

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97119440T PT2252300T (pt) 2008-02-22 2009-02-20 Utilização de 2,4-pirimidinadiaminas para tratamento da aterosclerose

Country Status (21)

Country Link
US (1) US8530466B2 (pt)
EP (1) EP2252300B1 (pt)
JP (1) JP5586482B2 (pt)
KR (1) KR101614555B1 (pt)
CN (1) CN102014917A (pt)
AU (1) AU2009215430B2 (pt)
BR (1) BRPI0907724B8 (pt)
CA (1) CA2715962C (pt)
CY (1) CY1118655T1 (pt)
DK (1) DK2252300T3 (pt)
ES (1) ES2610880T3 (pt)
HK (1) HK1150555A1 (pt)
HR (1) HRP20170050T1 (pt)
HU (1) HUE030307T2 (pt)
LT (1) LT2252300T (pt)
MX (1) MX2010009159A (pt)
PL (1) PL2252300T3 (pt)
PT (1) PT2252300T (pt)
RU (1) RU2490015C2 (pt)
SI (1) SI2252300T1 (pt)
WO (1) WO2009105675A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8450335B2 (en) 2008-06-27 2013-05-28 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
EP3825316A1 (en) 2009-12-23 2021-05-26 Takeda Pharmaceutical Company Limited Fused heteroaromatic pyrrolidinones as syk inhibitors
AU2011254550B2 (en) 2010-05-21 2013-11-07 Noviga Research Ab Novel pyrimidine derivatives
CN103096716B (zh) 2010-08-10 2016-03-02 西建阿维拉米斯研究公司 Btk抑制剂的苯磺酸盐
WO2012061299A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
WO2012061303A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
EP2637502B1 (en) 2010-11-10 2018-01-10 Celgene CAR LLC Mutant-selective egfr inhibitors and uses thereof
JP5886411B2 (ja) 2011-03-24 2016-03-16 ノビガ・リサーチ・エービーNoviga Research AB 新規のピリミジン誘導体
WO2012177714A1 (en) 2011-06-22 2012-12-27 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
EA028432B1 (ru) 2011-07-28 2017-11-30 Райджел Фармасьютикалз, Инк. Новые составы на основе (триметоксифениламино)пиримидинилов
CA2853498A1 (en) 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Methods of treating a bruton's tyrosine kinase disease or disorder
SG11201405691WA (en) 2012-03-15 2014-10-30 Celgene Avilomics Res Inc Solid forms of an epidermal growth factor receptor kinase inhibitor
CN104284584B (zh) 2012-03-15 2019-06-04 西建卡尔有限责任公司 表皮生长因子受体激酶抑制剂的盐
WO2014100748A1 (en) 2012-12-21 2014-06-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
MX2015009952A (es) 2013-02-08 2015-10-05 Celgene Avilomics Res Inc Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos.
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
JP7118642B2 (ja) * 2014-08-08 2022-08-16 アリ リサーチ ソシエタ ア レスポンサビリタ リミタータ センプリフィカタ 炎症性およびアレルギー性病変の治療に用いるための脂肪酸とパルミトイルエタノールアミドの混合物
EP3179858B1 (en) 2014-08-13 2019-05-15 Celgene Car Llc Forms and compositions of an erk inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ290681B6 (cs) * 1993-10-01 2002-09-11 Novartis Ag N-Fenyl-2-pyrimidinaminové deriváty, způsob jejich výroby, farmaceutické prostředky, které je obsahují a jejich použití
CN1142817A (zh) * 1993-10-12 1997-02-12 杜邦麦克制药有限公司 1n-烷基-n-芳基嘧啶胺及其衍生物
JP2002523497A (ja) * 1998-08-29 2002-07-30 アストラゼネカ・アクチエボラーグ ピリミジン化合物
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
JP4510442B2 (ja) * 2001-06-26 2010-07-21 ブリストル−マイヤーズ スクイブ カンパニー TNF−α発現のN−ヘテロ環インヒビター
CA2473910C (en) 2002-01-23 2011-03-15 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
US7288547B2 (en) 2002-03-11 2007-10-30 Schering Ag CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents
WO2003076437A1 (de) 2002-03-11 2003-09-18 Schering Aktiengesellschaft Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
TW200517057A (en) * 2003-09-22 2005-06-01 Basf Ag Fungicidal mixtures
WO2006027377A1 (en) * 2004-09-10 2006-03-16 Altana Pharma Ag Ciclesonide and syk inhibitor combination and methods of use thereof
DK1856135T3 (da) * 2005-01-19 2010-04-12 Rigel Pharmaceuticals Inc Prodrugs af 2,4-pyrimidindiamin-forbindelser og deres anvendelser
DE102005016634A1 (de) * 2005-04-12 2006-10-19 Merck Patent Gmbh Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
WO2007008541A2 (en) * 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
BR122021011788B1 (pt) * 2005-11-01 2022-01-25 Impact Biomedicines, Inc Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica
KR20090023698A (ko) 2006-06-15 2009-03-05 베링거 인겔하임 인터내셔날 게엠베하 2-아닐리노-4-아미노알킬렌아미노피리미딘
WO2008005538A2 (en) * 2006-07-05 2008-01-10 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
AU2008275918B2 (en) * 2007-07-17 2014-01-30 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as PKC inhibitors

Also Published As

Publication number Publication date
BRPI0907724B1 (pt) 2019-12-17
HRP20170050T1 (hr) 2017-03-10
ES2610880T3 (es) 2017-05-03
HK1150555A1 (zh) 2012-01-06
PL2252300T3 (pl) 2017-04-28
EP2252300A1 (en) 2010-11-24
EP2252300B1 (en) 2016-10-19
AU2009215430B2 (en) 2015-02-12
KR20100126422A (ko) 2010-12-01
WO2009105675A1 (en) 2009-08-27
RU2010138899A (ru) 2012-03-27
US20110046126A1 (en) 2011-02-24
US8530466B2 (en) 2013-09-10
HUE030307T2 (en) 2017-04-28
JP5586482B2 (ja) 2014-09-10
BRPI0907724B8 (pt) 2021-05-25
CA2715962C (en) 2017-03-07
JP2011513230A (ja) 2011-04-28
KR101614555B1 (ko) 2016-04-21
SI2252300T1 (sl) 2017-04-26
CY1118655T1 (el) 2017-07-12
LT2252300T (lt) 2017-02-10
DK2252300T3 (en) 2017-02-06
MX2010009159A (es) 2010-09-14
AU2009215430A1 (en) 2009-08-27
CA2715962A1 (en) 2009-08-27
BRPI0907724A2 (pt) 2017-06-13
RU2490015C2 (ru) 2013-08-20
CN102014917A (zh) 2011-04-13

Similar Documents

Publication Publication Date Title
HK1150555A1 (zh) 用於治療動脈硬化的 -嘧啶二元胺的應用
HRP20130357T1 (en) Novel compounds useful for the treatment of degenerative and inflammatory diseases.
ZA200902374B (en) Compositions useful for the treatment of diabetes
EP2101785A4 (en) TREATMENT OF IT SEC
EP2361089A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED FUNCTION OF -SYNUCLEINE
IL200796A0 (en) Device for the treatment of laundry using biocides
ZA201001264B (en) 1-amino-alkylcycohxane derivatives for the treatment of cochleat tinnitus
GB0711342D0 (en) Well treatment
GB0800145D0 (en) Skincare treatment
IL205137A0 (en) 5-cyanothienopyridines for the treatment of tumours
IL210290A0 (en) Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
HK1145634A1 (en) Treatment of atherosclerosis
ZA201007362B (en) Conjugates for the treatment of mesothelioma
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
EP2174956A4 (en) COMPOSITIONS FOR ANTIFIBRINOLYSIS THERAPY
ZA201005306B (en) 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use
GB0716784D0 (en) Well treatment
IL207668A0 (en) Beloxepin, its enantiomers, and analogs thereof for the treatment of pain
PL2252302T3 (pl) Kompozycja do leczenia zapalenia kości i stawów
GB0602857D0 (en) The treatment of sialorrhoea
EP2328577A4 (en) TREATMENT OF LOSS OF HEARING
GB0703491D0 (en) The treatment of hyperhidrosis
GB0703492D0 (en) The treatment of hyperhidrosis
GB0809319D0 (en) The treatment of puritus
GB0821381D0 (en) Compositions for the treatment of dry eye